会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 2. 发明申请
    • METALLICENIUM SALTS AND UTILIZATION THEREOF AS CYTOSTATIC AGENTS FOR COMBATTING CANCER
    • 金属盐的销售和利用作为用于组合癌症的细胞毒素
    • WO8503507A2
    • 1985-08-15
    • PCT/EP8500047
    • 1985-02-08
    • KOEPF MAIER PETRAKOEPF HARTMUTNEUSE EBERHARD WILHELM
    • KOEPF-MAIER PETRAKOEPF HARTMUTNEUSE EBERHARD WILHELM
    • C07F17/00A61K31/28A61K31/295A61P35/00C07F17/02
    • C07F17/02C07F17/00
    • Metallicenium salts having the general formula (I), wherein M represents Fe, Co, Ni, Ru or Os; C5H5-xRx and C5H5-yR'y represent cyclopentadienyl cycles which may be independently unsubstituted (x, y = 0) or substituted between 1 and 5 times (x, y = 1, 2, 3, 4 or 5), R and R' representing independently from each other similar or different substituents, and alkyl, cycloalkyl, hydroxyalkyl, aminoalkyl, halogenoalkyl, alkenyl, aryl, aralkyl, ferrocenyl, ferrocenylium, ferrocenylalkyl, acyl, halogenyl, trialkylsilyl, tricycloalkylsilyl, triarylsilyl, triaralkylsilyl or carboxyl, ester, amide or hydrazide groups, R and R' forming together an alkylen bridge with 2 to 4 bridge atoms; a, b, m and n are integers, m being 1 or 2 and n being 1, 2 or 3, while a.m = b.n; A representing a complexing or high density anion, stabilizing the metallicenium cation; as well as the solvates of said salts to be used as drugs, particularly as cytostatic agents for combatting cancer.
    • 具有通式(I)的金属盐,其中M表示Fe,Co,Ni,Ru或Os; C5H5-xRx和C5H5-yR'y代表环戊二烯基循环,其可以独立地是未取代的(x,y = 0)或取代1至5倍(x,y = 1,2,3,4或5),R和R 烷基,环烷基,羟基烷基,氨基烷基,卤代烷基,烯基,芳基,芳烷基,二茂铁基,二茂铁基,二茂铁基烷基,酰基,卤代,三烷基甲硅烷基,三环烷基甲硅烷基,三芳基甲硅烷基,三烷基甲硅烷基或羧基酯, 酰胺或酰肼基团,R和R'一起形成具有2至4个桥原子的亚烷基桥; a,b,m和n为整数,m为1或2,n为1,2或3,而a.m = b.n; A代表络合或高密度阴离子,稳定金属鎓阳离子; 以及用作药物的所述盐的溶剂化物,特别是用作抗癌作用的细胞抑制剂。
    • 9. 发明专利
    • DK456585A
    • 1985-10-07
    • DK456585
    • 1985-10-07
    • KOEPF MAIER PETRAKOEPF HARTMUTNEUSE EBERHARD WILHELM
    • KOEPF-MAIER PETRAKOEPF HARTMUTNEUSE EBERHARD WILHELM
    • C07F17/00A61K31/28A61K31/295A61P35/00C07F17/02C07FA61K
    • PCT No. PCT/EP85/00047 Sec. 371 Date Oct. 3, 1985 Sec. 102(e) Date Oct. 3, 1985 PCT Filed Feb. 8, 1985 PCT Pub. No. WO85/03507 PCT Pub. Date Aug. 15, 1985.Metallicenium salts of the general formula I [( eta 5-C5H-xRx)M( eta 5-C5H5-yR'y)]am+[A]bn-(I) in which M is Fe, Co, Ni, Ru or Os; C5H5-xRx and C5H5-yR'y denote cyclopendadienyl rings which, independently of one another, can be unsubstituted (x and y=0) or mono-, di-, tri-, tetra- or penta-substituted (x and y=1, 2, 3, 4 or 5), and in which R and R' independently of one another represent identical or different substituents and denote alkyl, cycloalkyl, hydroxyalkyl, aminoalkyl, halogenoalkyl, alkenyl, aryl, aralkyl, ferrocenyl, ferrocenylium, ferrocenylalkyl, acyl, halogenyl, trialkylsilyl, tricycloalkylsilyl, triarylsilyl, triaralkylsilyl or carboxyl, ester, amide or hydrazide groups, or R and R' together form an alkylene bridge with 2 to 4 bridge atoms; a, b, m and n are integers, and m has the value 1 or 2, n has the value 1, 2 or 3 and axm=bxn; and A is a complexating or very bulky anion which stabilizes the metallicenium cation; and solvates of these salts, for use as medicaments, in paticular as cytostatics in combating tumors susceptible thereto.